D.E. Shaw & Co
PLRX icon

D.E. Shaw & Co’s Pliant Therapeutics PLRX Stock Holding History

D.E. Shaw & Co’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,679
Closed -$115K – 4796
2024
Q2 		$115K Buy
+10,679
New +$138K ﹤0.01% 4147
2023
Q4 		– Sell
-48,999
Closed -$850K – 4541
2023
Q3 		$850K Sell
48,999
-369,664
-88% -$6.41M ﹤0.01% 3154
2023
Q2 		$7.59M Sell
418,663
-61,846
-13% -$1.46M 0.01% 1565
2023
Q1 		$12.8M Buy
480,509
+266,708
+125% +$7.59M 0.01% 1183
2022
Q4 		$4.13M Sell
213,801
-1,514
-0.7% -$31.7K ﹤0.01% 2269
2022
Q3 		$4.5M Buy
215,315
+143,260
+199% +$2.74M 0.01% 2221
2022
Q2 		$577K Sell
72,055
-18,054
-20% -$116K ﹤0.01% 4016
2022
Q1 		$632K Buy
90,109
+40,554
+82% +$414K ﹤0.01% 4229
2021
Q4 		$669K Sell
49,555
-26,439
-35% -$420K ﹤0.01% 4223
2021
Q3 		$1.28M Sell
75,994
-13,727
-15% -$291K ﹤0.01% 3403
2021
Q2 		$2.61M Buy
89,721
+13,374
+18% +$416K ﹤0.01% 2659
2021
Q1 		$3M Buy
+76,347
New +$2.48M ﹤0.01% 2229

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

D.E. Shaw & Co's PLRX Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Pliant Therapeutics (PLRX) in Q3 2024, closing a stake of 10,679 shares — an estimated $115K sold.

D.E. Shaw & Co first reported a position in PLRX in Q1 2021 and held it in 12 quarters. The position peaked at $12.8M in Q1 2023. 151 funds tracked by Wall St. Rank hold PLRX as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Pliant Therapeutics position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,679 Pliant Therapeutics shares in Q3 2024, an estimated $115K.
  • D.E. Shaw & Co first reported a position in Pliant Therapeutics in Q1 2021 and held it in 12 quarters.
  • D.E. Shaw & Co's Pliant Therapeutics position peaked at $12.8M in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.